Monoclonal gammopathy of undetermined significance historical perspective: Difference between revisions

	Monoclonal gammopathy of undetermined significance Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Monoclonal gammopathy of undetermined significance historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Monoclonal gammopathy of undetermined significance historical perspective
on Monoclonal gammopathy of undetermined significance historical perspective
Monoclonal gammopathy of undetermined significance historical perspective in the news
Blogs on Monoclonal gammopathy of undetermined significance historical perspective
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance
Risk calculators and risk factors for Monoclonal gammopathy of undetermined significance historical perspective

VisualWikitext

Revision as of 20:08, 9 August 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Historical Perspective

Discovery

Monoclonal gammopathy of undetermined significance was first discivered by Jan G. Waldenstrom in 1960 “essential hyperglobulinemia” or “benign monoclonal gammopathy” and then as monoclonal gammopathy of undetermined significance by Robert A. Kyle in 1978. ^[1]

Outbreaks

There have been several outbreaks of [disease name], which are summarized below:

Landmark Events in the Development of Treatment Strategies

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

Impact on Cultural History

Famous Cases

The following are a few famous cases of disease name:

References

↑ WALDENSTROM J (1960). "Studies on conditions associated with disturbed gamma globulin formation (gammopathies)". Harvey Lect. 56: 211–31. PMID 14004528.

Template:WH Template:WS

[pmid14004528-1] WALDENSTROM J (1960). "Studies on conditions associated with disturbed gamma globulin formation (gammopathies)". Harvey Lect. 56: 211–31. PMID 14004528.

[1]

@@ Line 6: / Line 6: @@
 ==Historical Perspective==
 ===Discovery===
-*[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
+*Monoclonal gammopathy of undetermined significance was first discivered by Jan G. Waldenstrom in 1960 “essential hyperglobulinemia” or “benign monoclonal gammopathy” and then as monoclonal gammopathy of undetermined significance by Robert A. Kyle in 1978. <ref name="pmid14004528">{{cite journal |vauthors=WALDENSTROM J |title=Studies on conditions associated with disturbed gamma globulin formation (gammopathies) |journal=Harvey Lect. |volume=56 |issue= |pages=211–31 |date=1960 |pmid=14004528 |doi= |url=}}</ref>
-*The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
-*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
-*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
 ==Outbreaks==
 There have been several outbreaks of [disease name], which are summarized below: